Cost-effectiveness of neonatal screening for Duchenne muscular dystrophy--how does this compare to existing neonatal screening for metabolic disorders?
Costs of screening a series of 18,152 newborn males for Duchenne muscular dystrophy (DMD) in Canada were evaluated. The final aim of neonatal screening for DMD is the avoidance of additional cases in the families identified. Total costs to avoid one case of DMD were estimated at Cdn. $172,000, while the incremental costs were found to be $83,000. Reagent costs, test sensitivity, efficacy of screening and compliance with genetic advice were identified as factors crucial for cost-effectiveness. Costs of neonatal screening for DMD are compared with costs of neonatal screening for inborn metabolic disorders. It is found that the two programmes are similar in costs. Earlier predictions of inordinate costs of screening for DMD are refuted.
Rosenberg
T
T
Department of Community Health Sciences, Faculty of Medicine, University of Manitoba, Winnipeg, Canada.
Jacobs
H K
HK
Thompson
R
R
Horne
J M
JM
D003362:Cost-Benefit Analysis; D005260:Female; D005820:Genetic Testing / Q000191:economics; D006801:Humans; D007231:Infant, Newborn; D008297:Male; D008350:Manitoba; D008661:Metabolism, Inborn Errors / Q000191:economics / Q000235:genetics / Q000517:prevention & control*; D009136:Muscular Dystrophies / Q000191:economics / Q000235:genetics / Q000517:prevention & control*; D015997:Neonatal Screening / Q000191:economics*; D010865:Pilot Projects; D011247:Pregnancy; D011296:Prenatal Diagnosis / Q000191:economics; D012307:Risk Factors